Equities analysts forecast that Antares Pharma Inc (NASDAQ:ATRS) will post ($0.04) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Antares Pharma’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.03). Antares Pharma reported earnings of ($0.03) per share in the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The company is expected to issue its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Antares Pharma will report full-year earnings of ($0.10) per share for the current year, with EPS estimates ranging from ($0.13) to ($0.06). For the next fiscal year, analysts expect that the business will report earnings of $0.18 per share, with EPS estimates ranging from $0.00 to $0.24. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. The firm had revenue of $23.29 million during the quarter, compared to analysts’ expectations of $17.46 million.

Several equities research analysts have recently weighed in on ATRS shares. Cowen started coverage on shares of Antares Pharma in a research report on Monday, February 25th. They issued an “outperform” rating and a $1.99 price target for the company. BidaskClub cut shares of Antares Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Raymond James upped their price target on shares of Antares Pharma from $5.25 to $5.65 and gave the stock a “strong-buy” rating in a research report on Monday, March 4th. TheStreet raised shares of Antares Pharma from a “d” rating to a “c” rating in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $4.50 price objective on shares of Antares Pharma in a research note on Monday, May 6th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Antares Pharma presently has a consensus rating of “Buy” and an average target price of $4.83.

In related news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $2.67, for a total transaction of $80,100.00. Following the completion of the transaction, the director now owns 190,213 shares in the company, valued at approximately $507,868.71. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Leonard S. Jacob sold 92,078 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $3.00, for a total transaction of $276,234.00. Following the transaction, the director now owns 301,970 shares of the company’s stock, valued at approximately $905,910. The disclosure for this sale can be found here. Insiders own 5.49% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Alpine Woods Capital Investors LLC bought a new position in shares of Antares Pharma during the 1st quarter worth approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Antares Pharma during the 4th quarter valued at approximately $31,000. Foundations Investment Advisors LLC acquired a new position in Antares Pharma during the 4th quarter valued at approximately $42,000. Virtu Financial LLC acquired a new position in Antares Pharma during the 4th quarter valued at approximately $45,000. Finally, Enterprise Bank & Trust Co acquired a new position in Antares Pharma during the 1st quarter valued at approximately $45,000. Hedge funds and other institutional investors own 42.36% of the company’s stock.

Shares of ATRS traded up $0.04 during mid-day trading on Friday, hitting $2.96. The company’s stock had a trading volume of 653,146 shares, compared to its average volume of 532,703. Antares Pharma has a 52-week low of $2.45 and a 52-week high of $3.96. The stock has a market capitalization of $481.36 million, a PE ratio of -74.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.90 and a current ratio of 2.28.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Read More: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.